Neurosense Therapeutics Ltd Stock Price, News & Analysis

NeuroSense Therapeutics announced the acceptance of two abstracts focusing on their lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS) treatment at the 2024 Annual Northeastern ALS Consortium Meeting. The abstracts will present data from NeuroSense's Phase 2b PARADIGM study.

Dr. Merit Cudkowicz from Massachusetts General Hospital will present clinical outcomes, while Dr. Cristian Lunetta from NEMO in Milan will discuss biomarker analysis. Recent findings showed PrimeC reduced disease progression by 36% (p=0.009) and improved survival rates by 43% compared to placebo, highlighting its potential as a breakthrough ALS therapy.

NeuroSense Therapeutics (Nasdaq: NRSN) announced the issuance of a pivotal U.S. patent for its novel PrimeC formulation, a leading drug candidate for treating Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's. The patent, titled 'Compositions comprising Ciprofloxacin and Celecoxib' (US Patent No. US 12,097,185), extends PrimeC's intellectual property protection by an additional four years, now covering it until 2042. PrimeC combines ciprofloxacin and celecoxib in unique doses with a slow-release technology to enhance therapeutic synergy and efficacy. Recent clinical findings showed PrimeC reduced disease progression by 36% and improved survival rates by 43% compared to placebo. NeuroSense CEO Alon Ben-Noon emphasized the innovative formulation's potential to optimize ALS treatment.

NeuroSense Therapeutics (Nasdaq: NRSN) has regained compliance with Nasdaq's minimum bid price requirement. The company, which develops treatments for severe neurodegenerative diseases, received notice from Nasdaq confirming that it has met the Rule 5550(a)(2) criteria. To achieve this, NeuroSense's ordinary shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, accomplished on September 20, 2024.

CEO Alon Ben-Noon expressed satisfaction with this development, viewing it as an important step that reflects the company's commitment to advancing PrimeC. He also mentioned positive momentum following Phase 2b trial results and plans to initiate a Phase 3 trial in the US, along with ongoing discussions with potential partners.

NeuroSense Therapeutics (Nasdaq: NRSN) has received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's ordinary shares have traded below $1.00 for 30 consecutive trading days. NeuroSense has until February 24, 2025, to regain compliance by maintaining a closing bid price of $1.00 or above for a minimum of 10 consecutive business days.

If compliance is not achieved by the deadline, NeuroSense may be eligible for an additional 180-day period to meet the requirement. The notification does not immediately affect the company's Nasdaq listing or the trading of its shares. However, failure to regain compliance within the allotted time could result in delisting from Nasdaq.

NeuroSense Therapeutics (Nasdaq: NRSN) has announced a private placement of $600,000 in ordinary shares and warrants. The company will sell 800,000 ordinary shares and warrants to purchase an additional 800,000 shares at a combined price of $0.75 per share and accompanying warrant, representing a 10% premium to the closing price on August 6, 2024. The warrants have a five-year term and an exercise price of $0.75 per share.

Notably, senior management, including the CEO, CFO, and CMO, as well as existing shareholders, are participating in the offering. The proceeds will be used for general corporate and working capital purposes. CEO Alon Ben-Noon expressed confidence in PrimeC's potential, citing positive results from the Phase 2b PARADIGM Study for ALS treatment.

NeuroSense Therapeutics (NASDAQ: NRSN) has announced positive 12-month iron biomarker data from its Phase IIb PARADIGM study of PrimeC in ALS patients. The results show significant improvements in iron regulation, aligning with previously reported 36% slower disease progression and 43% improved survival rates. Key findings include a decrease in ferritin levels and an increase in transferrin levels, indicating alleviation of ALS pathology. Iron levels remained stable over the 12-month dosing period, with a mean difference of 4.536 µmol/L compared to the placebo group. These positive changes in iron metabolism correlate with better functionality and survival rates in patients treated with PrimeC. The company is preparing to share additional data with the FDA and is in discussions with potential development partners for marketing opportunities.

NeuroSense has announced positive results from its 12-month PARADIGM Phase 2b study of PrimeC in ALS patients, showing a significant improvement in complication-free survival. Specifically, the study demonstrated a 57% difference in favor of PrimeC over placebo in the ITT population, and a 73% difference in the PP population. PrimeC also slowed disease progression by 36% and improved survival rates by 43% in prior reports. Additional data points showed improvements in Slow Vital Capacity and ALSFRS-R scores. These results will be submitted to the FDA to discuss the future of PrimeC. NeuroSense is optimistic about the potential of PrimeC as a treatment for ALS.

NeuroSense Therapeutics announced promising results from its PARADIGM Phase 2b study on PrimeC for ALS treatment. The 12-month data showed a 36% slower disease progression for participants on PrimeC compared to placebo (p=0.009). PrimeC also improved survival rates by 43%. Further analysis indicated a 40% improvement in ALSFRS-R scores and a 63% boost in survival for the per-protocol population on PrimeC. These findings support advancing to Phase 3 trials in the U.S. and Europe to further evaluate PrimeC's efficacy as a disease-modifying drug for ALS.

NeuroSense Therapeutics (NASDAQ: NRSN) announced a corporate update and Q1 2024 financial results. Their Phase 2b PARADIGM clinical trial showed a significant 43% slowing of disease progression in high-risk ALS patients treated with PrimeC. Upcoming milestones include 12-month clinical results in June 2024 and an FDA meeting in Q3 2024. Financially, the company reported stable R&D and administrative expenses at $1.88M and $1.11M, respectively. However, it faced a net loss of $5.4M for the quarter, with cash reserves at $0.74M as of March 31, 2024. Additional funding of $4.5M was secured in April 2024 through a direct offering.